Literature DB >> 29620613

Incidence, Risk Factors, and Outcomes of Clostridium difficile Infections in Kidney Transplant Recipients.

George J Li1, Justin Trac1, Shahid Husain1,2,3, Olusegun Famure1,4, Yanhong Li1, S Joseph Kim1,4,3,5.   

Abstract

BACKGROUND: Kidney transplant recipients (KTR) may be at increased risk for Clostridium difficile infections (CDI) but risk factors and outcomes in this population have not been well studied.
METHODS: An observational cohort study was conducted to determine the incidence, risk factors, and outcomes of CDI in KTR. A total of 1816 KTR transplanted between 2000 and 2013 at the Toronto General Hospital were included. Sixty-eight patients developed CDI. Controls were selected at a 4:1 ratio using risk-set sampling, and risk factors were explored using conditional logistic regression models. The impact of CDI on graft outcomes was evaluated using Cox proportional hazards models.
RESULTS: The incidence rate of CDI was 0.64 cases/100 person-years. Independent predictors of CDI included antibiotic use (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.35-6.15), increased duration of hospitalization posttransplant (OR, 1.04; 95% CI, 1.02-1.06]), receiving a deceased donor kidney (OR, 2.98; 95% CI, 1.47-6.05), and a history of biopsy-proven acute rejection (OR, 5.82; 95% CI, 2.22-15.26). In the Cox proportional hazards model, CDI was found to be an independent risk factor for the subsequent development of biopsy-proven acute rejection (hazard ratio, 2.18; 95% CI, 1.34-3.55).
CONCLUSIONS: Our results confirm that transplant-specific factors place KTR at a higher risk for CDI. Clostridium difficile infections may increase the risk of adverse outcomes, such as biopsy-proven acute rejection. These findings emphasize the importance of preventive strategies to reduce the morbidity associated with CDI in KTR.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29620613     DOI: 10.1097/TP.0000000000002199

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Emma E Ilett; Marie Helleberg; Joanne Reekie; Daniel D Murray; Signe M Wulff; Mark P Khurana; Amanda Mocroft; Gedske Daugaard; Michael Perch; Allan Rasmussen; Søren S Sørensen; Finn Gustafsson; Niels Frimodt-Møller; Henrik Sengeløv; Jens Lundgren
Journal:  Open Forum Infect Dis       Date:  2019-02-19       Impact factor: 3.835

2.  Incidence and Outcomes Associated With Clostridioides difficile Infection in Solid Organ Transplant Recipients.

Authors:  Seyed M Hosseini-Moghaddam; Bin Luo; Sarah E Bota; Shahid Husain; Michael S Silverman; Nick Daneman; Kevin A Brown; J Michael Paterson
Journal:  JAMA Netw Open       Date:  2021-12-01

Review 3.  Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines.

Authors:  Federico Coccolini; Mario Improta; Massimo Sartelli; Kemal Rasa; Robert Sawyer; Raul Coimbra; Massimo Chiarugi; Andrey Litvin; Timothy Hardcastle; Francesco Forfori; Jean-Louis Vincent; Andreas Hecker; Richard Ten Broek; Luigi Bonavina; Mircea Chirica; Ugo Boggi; Emmanuil Pikoulis; Salomone Di Saverio; Philippe Montravers; Goran Augustin; Dario Tartaglia; Enrico Cicuttin; Camilla Cremonini; Bruno Viaggi; Belinda De Simone; Manu Malbrain; Vishal G Shelat; Paola Fugazzola; Luca Ansaloni; Arda Isik; Ines Rubio; Itani Kamal; Francesco Corradi; Antonio Tarasconi; Stefano Gitto; Mauro Podda; Anastasia Pikoulis; Ari Leppaniemi; Marco Ceresoli; Oreste Romeo; Ernest E Moore; Zaza Demetrashvili; Walter L Biffl; Imitiaz Wani; Matti Tolonen; Therese Duane; Sameer Dhingra; Nicola DeAngelis; Edward Tan; Fikri Abu-Zidan; Carlos Ordonez; Yunfeng Cui; Francesco Labricciosa; Gennaro Perrone; Francesco Di Marzo; Andrew Peitzman; Boris Sakakushev; Michael Sugrue; Marja Boermeester; Ramiro Manzano Nunez; Carlos Augusto Gomes; Miklosh Bala; Yoram Kluger; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-08-09       Impact factor: 5.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.